PsychoGenics, Inc., Tarrytown, NY 10591, USA.
Pharmacol Biochem Behav. 2010 Jun;95(4):449-56. doi: 10.1016/j.pbb.2010.03.006. Epub 2010 Mar 25.
The present studies assessed the potential abuse liability and likely mechanism(s) of action of the wake-promoting agent modafinil.
Experiments assessed the locomotor sensitization (LS) and discriminative stimulus (DS) properties of modafinil in mouse and rat, respectively. Comparative data were generated with a range of psychostimulants and monoamine reuptake inhibitors.
Repeated administration of d-amphetamine and cocaine, psychostimulants with high abuse liability, resulted in the induction and expression of LS in mice. Bupropion and caffeine, two psychostimulants not abused in humans, were not associated with LS. GBR12909 induced LS during repeated exposure, but there was no evidence of expression of LS after acute challenge following withdrawal. In contrast, repeated administration of modafinil resulted in the expression, but not induction, of LS. d-amphetamine, but not the mu-opioid agonist morphine or the nAChR agonist nicotine, fully substituted for the cocaine DS in rats. The selective dopamine transporter (DAT) inhibitor GBR12909 fully substituted, the preferential norepinephrine transporter (NET) inhibitor desipramine partially substituted, and the selective serotonin reuptake inhibitor citalopram failed to substitute for cocaine. Modafinil fully substituted for cocaine, similar to the mixed DAT/NET inhibitor bupropion.
Two preclinical assays indicated potential abuse liability of modafinil; drug discrimination studies suggest DAT blockade by modafinil is a likely mechanism of action in vivo.
本研究评估了觉醒促进剂莫达非尼的潜在滥用倾向和可能的作用机制。
实验分别评估了莫达非尼在小鼠和大鼠中的运动敏化(LS)和辨别刺激(DS)特性。比较数据是用一系列精神兴奋剂和单胺再摄取抑制剂生成的。
重复给予具有高滥用倾向的精神兴奋剂安非他命和可卡因,导致小鼠产生 LS 的诱导和表达。两种在人类中不被滥用的精神兴奋剂安非他命和咖啡因与 LS 无关。GBR12909 在重复暴露期间诱导 LS,但在停药后急性挑战后没有 LS 表达的证据。相比之下,重复给予莫达非尼导致 LS 的表达,但不诱导 LS。安非他命,但不是阿片 μ 受体激动剂吗啡或烟碱型乙酰胆碱受体激动剂尼古丁,完全取代了可卡因在大鼠中的 DS。选择性多巴胺转运体(DAT)抑制剂 GBR12909 完全取代,选择性去甲肾上腺素转运体(NET)抑制剂地昔帕明部分取代,而选择性 5-羟色胺再摄取抑制剂西酞普兰不能取代可卡因。莫达非尼完全取代可卡因,类似于混合 DAT/NET 抑制剂安非他命。
两项临床前检测表明莫达非尼具有潜在的滥用倾向;药物辨别研究表明,莫达非尼在体内的作用机制可能是 DAT 阻断。